GlaxoSmithKline And Merck KGaA Position For The Next Wave In Immuno-Oncology
GlaxoSmithKline And Merck KGaA Position For The Next Wave In Immuno-Oncology.....»»
Merck KGaA price target lowered to EUR 101 from EUR 105 at Morgan Stanley
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
PDS Biotechnology Reports Full Year 2019 Financial Results and Provides Business Update
PRINCETON, N.J., March 27, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation ("PDS Biotechnology") (NASDAQ:PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on T-cell.....»»
CStone Pharmaceuticals Reports 2019 Annual Financial Results
SHANGHAI, March 26, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone"; HKEX: 2616), a leading biopharmaceutical company focused on developing and commercializing innovative immuno-oncology (IO) therapies and molecularly-targeted precision medi.....»»
HELIX BIOPHARMA CORP. ANNOUNCES FISCAL SECOND QUARTER 2020 RESULTS
RICHMOND HILL, Ontario, March 16, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: "HBP"), a an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the fiscal .....»»
Checkpoint Therapeutics Reports Full-Year 2019 Financial Results and Recent Corporate Highlights
NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, develop.....»»
Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2019
CAMBRIDGE, Mass., March 10, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies.....»»
UBS backs Neutral on Merck KGaA after Q4 results
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Kaleido expects in vivo findings from immuno-oncology programs in 4Q20
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Forty Seven"s stock rockets Gilead"s $4.9 billion buyout deal
Shares of Forty Seven Inc. shot up 61% in premarket trading Monday, after the immuno-oncology company agreed to be acquired by Gilead Sciences Inc. in a cash deal valued at $4.9 bill.....»»
Atreca in strategic research collaboration with Merck for oncology
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Merck’s Spin-Off May Create Operational Risks for the Year Ahead
Merck finds itself in a position of being an acquirer of sorts at the same time it wants to spin out part of its operations. Executing this effort may create some operational uncertainty inside of........»»
Merck CEO says "in a position of operational and financial strength"
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Merck to retain current growth pillars of Oncology, Vaccines, Animal Health
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Astellas ramps up M&A, buys U.S. biotech Xyphos for as much as $665 million
Astellas Pharma Inc has bought U.S.-based Xyphos Biosciences Inc to expand its immuno-oncology business, a deal worth up to $665 million including potential development milestones and its second acquisition announced this month......»»
BioLineRx (BLRX) Presents At ESMO Immuno-Oncology Congress 2019 - Slideshow
BioLineRx (BLRX) Presents At ESMO Immuno-Oncology Congress 2019 - Slideshow.....»»
Exicure shares rise on immuno-oncology trial
Shares of Exi.....»»
France"s Sanofi to buy Synthorx for $2.5B
The move helps Sanofi boost its immuno-oncology pipeline......»»
Merck KGaA participates in a conference call with JPMorgan
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Detailing GlaxoSmithKline"s Growth Opportunities In Oncology And Upcoming BCMA Data
Detailing GlaxoSmithKline"s Growth Opportunities In Oncology And Upcoming BCMA Data.....»»
Personalis announces collaboration with Merck KGaA
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»